25 results
1a. Determine whether the effect of low-molecular-weight heparin can be explained by aspirin resistance. 1b. Assess the consistency of aspirin resistance during and after pregnancy measured with several complementary devices. 2. Determine…
This study is set-up to evaluate the safety and tolerability of CCX168 in subjects with mild to moderate AARV on a background of cyclophosphamide treatment. It will assess the possibility to optimize the treatment with CCX168 and to reduce the side…
To evaluate safety of 3-months versus standard 12-months of DAPT
To demonstrate non-inferiority of continuation of platelet inhibiting drugs in eyelid surgery regarding the risk of haemorrhagic complications.
The main objective of this study is to determine the role of glycaemic control in diabetes mellitus in the occurrence of acetylsalicylic acid resistance, the secondary objective is to determine the effect of increased dosing on acetylsalicylic acid…
Determine effect of asprin and simvastatin on platelet and monocyte gene expression in vivo.
To investigate whether COX-2 inhibition enhances platelet aggregation by suppression of prostacyclin formation without suppressing thromboxane formation
-To assess the feasibility of relatively frequent measurements of whole blood platelet aggregometry using collagen as inducer;-To assess the effects of ASA treatment on collagen-induced platelet aggregation (primary endpoint);-To investigate the…
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide…
To study the effectiveness of low-dose rivaroxaban with aspirin in improving endothelial function in patients with symptomatic or stable PAD.
The primary aim of the GENPAD study is to evaluate the ability of genotype-guided antithrombotic treatment to reduce adverse clinical events related to arterial thrombosis in patients with peripheral arterial disease. Secondary aims are to evaluate…
Primary Objective: to obtain reliable estimates of the rates of vascular death and non-fatal stroke in patients with atrial fibrillation and a recent anticoagulation-associated ICH who are treated with apixaban versus those who are treated with APDs…
The primary objective of the study is to assess the efficacy and safety of 3 different treatment arms (bevacizumab alone, atezolizumab-bevacizumab combination with acetylsalicylic acid and atezolizumab-bevacizumab combination with placebo) in…
Dual Primary Objectives:* To determine if apixaban is noninferior to VKA (INR target range 2.0-3.0) on the combined endpoint of ISTHmajor or clinically relevant non-major bleeding in patients with NVAF who develop ACS or undergo PCI withplanned…
Primary objectives:*To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces therisk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with…
The primary objective is to evaluate the efficacy of avacopan compared to placebo based on histologic changes in kidney biopsies taken before and during treatment.The secondary objectives of this study include evaluation of:1. The safety of avacopan…
To determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin.
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/…
The primary objective of this study is to prove noninferiority regarding safety and effectiveness of 30-45 day of DAPT followed by Prasugrel-monotherapy versus standard 12 months of DAPT in patients admitted for STEMI treated by primary PCI.The…
The Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients (LEGACY) trial will investigate whether omitting aspirin reduces the rate of major or minor bleeding while remaining non-inferior to the current…